Abstracts Archive - Page 1480 of 2607 - ACR Meeting Abstracts

Abstract Number: 1391 • 2017 ACR/ARHP Annual Meeting
Ultrasound Response to Tocilizumab in Surgically Replaced Joints and Surgically Operated Joint Areas of Rheumatoid Arthritis Patients
Evan Choate¹, Gurjit S. Kaeley², Jenny Brook³, John Fitzgerald⁴, David Elashoff⁵ and Veena K. Ranganath⁶, ¹David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, ³Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁴David Geffen School of Medicine, Division of Rheumatology, Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, ⁵David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, ⁶Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Rheumatoid Arthritis (RA) disease activity outcomes are used for treatment decisions (ie. DAS28-ESR). Surgically operated joints (SOJ) are assumed not to respond to therapy…
Abstract Number: 1392 • 2017 ACR/ARHP Annual Meeting
Effect Size Comparison of Ultrasound Measures in Rheumatoid Arthritis
Veena K. Ranganath¹, David Elashoff², Jenny Brook³, Ami Ben-Artzi⁴, Geraldine Navarro⁵, Lynnette Avedikian-Tatosyan⁶, George Karpouzas⁷, William Martin⁵, Tanaz A. Kermani⁵, Soo Choi⁵ and Gurjit S. Kaeley⁸, ¹Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, ³Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁴Medicine, Cedars, Beverly Hills, CA, ⁵Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁶Healthcare Partners, Los Angeles, CA, ⁷Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁸Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL
Background/Purpose: Currently there are several outcome metrics used for the assessment and quantification of musculoskeletal (MSK) ultrasound inflammatory burden in rheumatoid arthritis (RA). This study…
Abstract Number: 1393 • 2017 ACR/ARHP Annual Meeting
Patient Characteristics, Treatment Strategy or Investigator Effect: An Analysis of Factors Driving Variation in Outcomes in Early Rheumatoid Arthritis
Cheryl Barnabe¹, Orit Schieir², Glen Hazlewood¹, Susan J. Bartlett³, Carol A Hitchon⁴, Janet E. Pope⁵, Gilles Boire⁶, Edward C. Keystone⁷, Diane Tin⁸, B Haraoui⁹, Vivian P. Bykerk¹⁰ and Carter Thorne¹¹, ¹Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁶Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ¹⁰2-005, Mt Sinai Hospital, Toronto, ON, Canada, ¹¹University of Toronto, Newmarket, ON, Canada
Background/Purpose: Outcomes in ERA are largely thought to reflect individual prognostic factors and treatment strategy employed. We hypothesize that an additional factor may be the…
Abstract Number: 1394 • 2017 ACR/ARHP Annual Meeting
Comparison of Improvements in Disease Activity between Classes of Biologic Disease Modifying Anti-Rheumatic Drugs in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort
Richard Gliklich¹, Zhaohui Su², Gregory Donadio¹, Tom Brecht², Costas Boussios², Francis O’Donovan³, Charles Kekeh³, Anna Lafontant², Kathryn Starzyk² and Vandana Menon², ¹OM1, Inc, Cambridge, MA, ²Research, OM1, Inc, Cambridge, MA, ³Data Science, OM1, Inc, Cambridge, MA
Background/Purpose: RA is estimated to affect approximately 1.3 million adults in the US and accounts for a significant proportion of US health care spend with…
Abstract Number: 1395 • 2017 ACR/ARHP Annual Meeting
Patient Reported Outcomes in Rheumatoid Arthritis: Best Domain, Best Interface
Iris Navarro-Millán¹, Anna Cornelius-Schecter¹, Aprajita Jagpal², Bernadette Johnson³, Liana Fraenkel⁴, Monika M. Safford¹ and Jeffrey R. Curtis², ¹Weill Cornell Medical College, New York, NY, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT
Background/Purpose: Quantifiable measures of patients’ symptoms such as patient reported outcomes (PROs) provides the physician with quantifiable information of subjective symptoms experienced by patients with…
Abstract Number: 1396 • 2017 ACR/ARHP Annual Meeting
Can 3 0-10 Physician Visual Analog Scales (VAS) to Assess Levels of Inflammation, Damage and Distress Offer Comprehensive Quantitative Data That May be As Informative As Detailed, Formal Swollen and Tender Joint Counts?
MJ Bergman¹ and Theodore Pincus², ¹Drexel University College of Medicine, Philadelphia, PA, ²Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Management of patients with rheumatoid arthritis (RA) remains primarily according to a patient history and physical examination, unlike in many other chronic diseases, in…
Abstract Number: 1397 • 2017 ACR/ARHP Annual Meeting
American College of Rheumatology Response Rates Determined Using 28 Versus 68/66 Joint Count in Patients with Rheumatoid Arthritis Receiving Tofacitinib in Phase 3 Studies
Josef S. Smolen¹, William Shergy², Grace C. Wright³, Ryan DeMasi⁴, Kenneth Kwok⁵, Christopher F Mojcik⁵, Noriko Iikuni⁵, Svitlana Tatulych⁶ and Gustavo Citera⁷, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Rheumatology Associates of North Alabama, Huntsville, AL, ³NYU Langone Medical Center, New York, NY, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Groton, CT, ⁷Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In a clinical trial setting, standard criteria for measuring the…
Abstract Number: 1398 • 2017 ACR/ARHP Annual Meeting
Sleep and Physical Activity: An Objective Profile of People with Rheumatoid Arthritis
Sean McKenna¹, Marie Tierney², Sandy Fraser³, Aoife O'Neill⁴ and Norelee Kennedy¹, ¹Department of Clinical Therapies, University of Limerick, Ireland, Limerick, Ireland, ²Discipline of General Practice, National University of Galway, Ireland, Galway, Ireland, ³Department of Rheumatology, University Hospitals Limerick, Ireland, Limerick, Ireland, ⁴Department of Mathematics, University of Limerick, Ireland, Limerick, Ireland
Background/Purpose: Regular physical activity is important for people with rheumatoid arthritis (RA). Sleep requirements for adults should be on a ‘sleep needs spectrum’ of between…
Abstract Number: 1399 • 2017 ACR/ARHP Annual Meeting
Tissues Are Differently Modulated By Tocilizumab and Methotrexate; Assessment of Connective Tissue Metabolites in the Ambition Study
Anne C. Bay-Jensen¹, Anne Sofie Siebuhr¹, Christian S. Thudium² and Morten Asser Karsdal¹, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
Background/Purpose: The response to any treatment in rheumatoid arthritis (RA) is assessed by symptomatic changes, such as swollen joint count and DAS28. However, such assessments…
Abstract Number: 1400 • 2017 ACR/ARHP Annual Meeting
Beneficial Effect of Anti-IL-6 Blockade on Insulin Resistance and Insulin Sensitivity in Patients with Rheumatoid Arthritis
Raquel López-Mejías¹, Fernanda Genre¹, Sara Remuzgo-Martínez¹, Begoña Ubilla¹, Veronica Mijares¹, Jaime Calvo-Alen², Javier Llorca³, Santos Castañeda⁴ and Miguel Angel González-Gay⁵, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Rheumatology Department, Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ³Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁴Hospital Universitario La Princesa. IIS-IP. Madrid. Spain, Madrid, Spain, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL. School of Medicine, University of Cantabria., Santander, Spain
Background/Purpose: Systemic inflammation, insulin resistance, and endothelial dysfunction were implicated in the development of cardiovascular disease in rheumatoid arthritis (RA) [1-3]. Since insulin resistance can…
Abstract Number: 1401 • 2017 ACR/ARHP Annual Meeting
Persistence of Mast Cell-Rich Synovitis Is Associated with Lack of Response to Synthetic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
Felice Rivellese, Frances Humby, Sara Pagani, Alessandra Nerviani and Costantino Pitzalis, Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
Background/Purpose: Mast cells (MCs) are immune cells infiltrating the synovial membrane and implicated in the pathogenesis of Rheumatoid Arthritis, but their strict contribution to disease…
Abstract Number: 1402 • 2017 ACR/ARHP Annual Meeting
In RA, Becoming Seronegative over the 1st Year of DMARD Treatment Does Not Improve Chances of Drug-Free Remission in the Long-Term
Emma de Moel¹, Veerle Derksen¹, LA Trouw¹, Holger Bang², Yvonne P. Goekoop-Ruiterman³, GM Steup-Beekman^1,4, Tom W.J. Huizinga⁵, Cornelia F Allaart⁵, Rene E.M. Toes¹ and Diane van der Woude⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Rheumatology, HAGA hospital, The Hague, Netherlands, ⁴Rheumatology, Haaglanden Medical Center, The Hague, Netherlands, ⁵Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patients with RA harbor autoantibodies of various isotypes and directed against several post-translational modifications. Baseline seropositivity is a poor prognostic factor for sustained drug-free…
Abstract Number: 1403 • 2017 ACR/ARHP Annual Meeting
Mediterranean Diet Is Inversely Associated with Risk of Rheumatoid Arthritis: A Swedish Population Based Case-Control Study
Daniela Di Giuseppe¹, Kari Johansson², Johan Askling³ and Lars Alfredsson⁴, ¹Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Karolinska Institutet, Solna, Sweden, ³Unit of Clinical Epidemiology, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The Mediterranean Diet has been associated with lower mortality and risk of cardiovascular diseases and cancer. Although its components have been analyzed in several…
Abstract Number: 1404 • 2017 ACR/ARHP Annual Meeting
Hydrogen Sulfide Metabolism and Rheumatoid Arthritis
Alexis Guice¹, Richa Dhawan², Sibile Pardue³ and Christopher Kevil⁴, ¹INTERNAL MEDICINE, LSU UNIVERSITY HEALTH, SHREVEPORT, LA, ²INTERNAL MEDICINE, SECTION OF RHEUMATOLOGY, LSU UNIVERSITY HEALTH, SHREVEPORT, LA, ³LSU UNIVERSITY HEALTH, SHREVEPORT, LA, ⁴PATHOLOGY,MOLECULAR CELLULAR PHYSIOLOGY AND CELL BIOLOGY AND ANATOMY, LSU UNIVERSITY HEALTH, SHREVEPORT, LA
Background/Purpose: Hydrogen sulfide (H2S) is an endogenous gasotransmitter known to play a role in inflammation. While levels of hydrogen sulfide have been studied in patient…
Abstract Number: 1405 • 2017 ACR/ARHP Annual Meeting
Using Flow and Mass Cytometry to Demonstrate Robust Tissue Processing to Query Molecular Heterogeneity in Phase 1 of the Accelerating Medicines Partnership (AMP) – RA Network
Kevin Wei¹, Deepak Rao², Fan Zhang³, Chamith Fonseka³, Kamil Slowikowski³, Joshua Keegan⁴, Laura T. Donlin⁵, Jason Turner⁶, Mandy J. McGeachy⁷, Nida Meednu⁸, David Lieb⁹, Stephen Kelly¹⁰, Susan M. Goodman¹¹, David L. Boyle¹², William H. Robinson¹³, Paul J. Utz¹⁴, Gary S. Firestein¹⁵, Harris Perlman¹⁶, Edward F. DiCarlo¹⁷, Costantino Pitzalis¹⁰, Andrew Filer¹⁸, Brendan Boyce¹⁹, Ellen M. Gravallese²⁰, Chad Nusbaum²¹, James Lederer⁴, Nir Hacohen^22,23,24, Peter Gregersen²⁵, Larry W. Moreland²⁶, Michael Holers²⁷, Vivian P. Bykerk²⁸, Soumya Raychaudhuri³, Michael Brenner²⁹ and Jennifer H. Anolik⁸, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁶Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁷Medicine, University of Pittsburgh, Pittsburgh, PA, ⁸Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁹Broad Institute, Cambridge, MA, ¹⁰Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ¹¹Medicine, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ¹²University of California San Diego, La Jolla, CA, ¹³Stanford University School of Medicine, Stanford, CA, ¹⁴Medicine, Stanford University School of Medicine, Stanford, CA, ¹⁵Medicine, University of California San Diego, La Jolla, CA, ¹⁶Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University Feinberg School of Medicine,, Chicago, IL, ¹⁷Laboratory Medicine, Hospital for Special Surgery, New York, NY, ¹⁸Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ¹⁹University of Rochester Medical Center, Rochester, NY, ²⁰Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA, ²¹The Broad Institute and Harvard, Cambridge, MA, ²²Harvard Medical School, Boston, MA, ²³Massachusetts General Hospital, Charlestown, MA, ²⁴Broad Institute of MIT and Harvard, Cambridge, MA, ²⁵The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, ²⁶Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²⁷Medicine, Division of Rheumatology, University of Colorado Denver, Aurora, CO, ²⁸Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ²⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Discovery and application of new therapies for rheumatoid arthritis (RA) has been hampered by multiple factors, including disease heterogeneity and the lack of well…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].